ArticlePharmaceuticals (Basel, Switzerland)2026
Real-World Comparison of Biosimilar Ranibizumab (Ranieyes) and Innovator Ranibizumab (Lucentis/Accentrix) Across Multiple Retinal Vascular Diseases (The BRIO Study).
Debdulal Chakraborty et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.